Roberto Pili
Affiliations: | Cellular and Molecular Biology | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Cell Biology, PharmacyGoogle:
"Roberto Pili"Children
Sign in to add trainee| Paula C. Sotomayor Fahrenkrog | grad student | 2013 | SUNY Buffalo |
| Swathi Ramakrishnan | grad student | 2014 | SUNY Buffalo |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Trott JF, Aboud OA, McLaughlin B, et al. (2022) Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer. Kidney360. 1: 376-388 |
| Goldsamt A, Damayanti NP, De Nigris F, et al. (2020) Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions. Cancer Journal (Sudbury, Mass.). 26: 399-406 |
| Voss MH, Gordon MS, Mita M, et al. (2020) Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer |
| Kays JK, Koniaris LG, Cooper CA, et al. (2020) The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers. 12 |
| Affronti HC, Rowsam AM, Pellerite AJ, et al. (2020) Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nature Communications. 11: 52 |
| Trott JF, Abu Aboud O, McLaughlin B, et al. (2020) Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer Kidney360. 1: 376-388 |
| Adra N, Hauke RJ, Kaimakliotis HZ, et al. (2020) Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295. Journal of Clinical Oncology. 38: TPS587-TPS587 |
| Pili R, Adra N, Damayanti N, et al. (2020) Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients. Journal of Clinical Oncology. 38: 5064-5064 |
| Wood A, George S, Adra N, et al. (2019) Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Investigational New Drugs |
| Shen L, Pili R. (2019) Tasquinimod targets suppressive myeloid cells in the tumor microenvironment. Oncoimmunology. 8: e1072672 |